The development of organ-on-a-chip models aims to reduce the (expensive) high drug failure rates that exist in clinical trials. A Florida biotech firm recently reported that their multi-organ “human-on-a-chip” system maintains cellular viability over 28 days in serum-free conditions, using a pumpless system. To learn more about the vision for multi-organ “human-on-a-chip” models, we caught up with James Hickman, Chief Science Officer of Hesperos Inc.Read More
A recently announced collaboration between Juvenescence, Ltd., and NetraMark Corp. has yielded a new joint venture, NetraPharma, which aims to fight aging-related conditions. We spoke with NetraMark founder Dr. Joseph Geraci to find out more about how the process of targeting and treating neurodegenerative disorders will be radically changed by AI.Read More
Botulinum neurotoxins are widely used in both therapeutic and cosmetic applications, but Ipsen says that their new rBoNT-E toxin is a step up from compounds based on the much more widely used serotype A toxin. We spoke to Ipsen Senior Vice President Neurosciences R&D, Philippe Picaut, to find out more.Read More
Clinical treatments for neurological and mood disorders like social anxiety disorder and major depressive disorder have failed to show consistent efficacy in treating patients. VistaGen Therapeutics is aiming to correct that. We talked to VistaGen’s CEO, Shawn Singh, about the need for treatments in this area and why Vistagen thinks their compounds AV-101 and PH94B could be promising therapies.Read More
What do biomarkers and a 1990s TGIF party have in common? Find out here...
TBIcheck is a rapid point-of-care diagnostic device that detects biomarkers indicative of mild traumatic brain injury. To find out more, we spoke with the head of the Biomedical Proteomics Group, Jean-Charles Sanchez.
We recently spoke to Karoly Nikolich, chairman and chief executive officer of Alkahest, a clinical-stage biotechnology company, to learn more about their approach to developing therapeutics for both neurodegenerative and age-related diseases.Read More
NeuroBo Pharmaceuticals’ first lead candidate, NB-01, is positioned as a potential treatment for diabetic neuropathic pain. The candidate, which in 2018 will move into a phase III clinical trial, uses extracts of two species of the plant genus Dioscorea, used in traditional medicine for centuries, but never yet subject to systematic study. We caught up with NeuroBo’s Mark Versavel and Nandan Padukone to find out more.